Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report
Delayed Nasdaq  -  04:00 2022-10-05 pm EDT
18.94 USD   -0.53%
09/27Stifel Adjusts Price Target on Deciphera Pharmaceuticals to $18 From $11, Reiterates Hold Rating
MT
09/12Piper Sandler Raises Deciphera Pharmaceuticals Price Target to $18 From $13, Maintains Neutral Rating
MT
09/12SVB Securities Adjusts Deciphera Pharmaceuticals' Price Target to $25 from $21, Maintains Outperform Rating
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/29/2022 09/30/2022 10/03/2022 10/04/2022 10/05/2022 Date
17.62(c) 18.5(c) 18.3(c) 19.04(c) 18.94(c) Last
826 292 1 399 518 1 010 897 783 655 583 037 Volume
-3.45% +4.99% -1.08% +4.04% -0.53% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 130 M - -
Net income 2022 -178 M - -
Net cash position 2022 190 M - -
P/E ratio 2022 -7,48x
Yield 2022 -
Sales 2023 156 M - -
Net income 2023 -168 M - -
Net cash position 2023 203 M - -
P/E ratio 2023 -8,47x
Yield 2023 -
Capitalization 1 266 M 1 266 M -
EV / Sales 2022 8,29x
EV / Sales 2023 6,83x
Nbr of Employees 280
Free-Float 72,4%
More Financials
Company
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering medicines to patients for the treatment of cancer. The Company developed a switch-control kinase inhibitor platform in kinase biology to execute its strategy to develop a broad portfolio of medicines. The Company has one approved drug, QINLOCK, which is a switch-control kinase inhibitor for the treatment... 
More about the company
Ratings of Deciphera Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about DECIPHERA PHARMACEUTICALS, INC.
09/27Stifel Adjusts Price Target on Deciphera Pharmaceuticals to $18 From $11, Reiterates Ho..
MT
09/12Piper Sandler Raises Deciphera Pharmaceuticals Price Target to $18 From $13, Maintains ..
MT
09/12SVB Securities Adjusts Deciphera Pharmaceuticals' Price Target to $25 from $21, Maintai..
MT
09/12HC Wainwright Adjusts Deciphera Pharmaceuticals' Price Target to $25 from $20, Reiterat..
MT
09/12Deciphera Pharmaceuticals, Inc. : Regulation FD Disclosure, Financial Statements and Exhib..
AQ
09/11Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT..
BU
09/11Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT..
CI
09/10Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation D..
BU
09/10Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation D..
CI
09/01Deciphera Pharmaceuticals, Inc. to Host Virtual Investor Event Featuring Key Opinion Le..
BU
08/29Deciphera Pharmaceuticals Shares Rise After Cowen Initiates Coverage
MT
08/29Cowen Starts Deciphera Pharmaceuticals at Outperform With $25 Price Target
MT
08/19Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5..
BU
08/10Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Stud..
BU
08/10Deciphera Pharmaceuticals, Inc. Announces Publication of Intrigue Phase 3 Clinical Stud..
CI
More news
News in other languages on DECIPHERA PHARMACEUTICALS, INC.
09/11Deciphera Pharmaceuticals, Inc. Présente des données actualisées de phase 1/2 pour le V..
09/10Deciphera Pharmaceuticals, Inc. présente les premières données de phase 1 en escalade d..
08/29Les actions de Deciphera Pharmaceuticals augmentent après que Cowen ait initié la couve..
08/10Deciphera Pharmaceuticals, Inc. annonce la publication des résultats de l'étude cliniqu..
08/04Deciphera Pharmaceuticals réduit sa perte au deuxième trimestre et augmente son chiffre..
More news
Analyst Recommendations on DECIPHERA PHARMACEUTICALS, INC.
More recommendations
ETFs positioned on DECIPHERA PHARMACEUTICALS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Virtus LifeSci Biotech Products ETF - USD1.86%6.22%United_States
SPDR S&P Biotech ETF - USD0.57%6.55%United_States
ETFs S&P Biotech ETF - Distributing - AUD0.49%5.64%-United_States
IShares Micro-Cap ETF - USD0.14%6.19%United_States
IShares Nasdaq US Biotechnology - USD0.1%1.82%United_States
More ETFs positioned on DECIPHERA PHARMACEUTICALS, INC.
Chart DECIPHERA PHARMACEUTICALS, INC.
Duration : Period :
Deciphera Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DECIPHERA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 18,94 $
Average target price 18,78 $
Spread / Average Target -0,86%
EPS Revisions
Managers and Directors
Steven L. Hoerter President & Chief Executive Officer
Thomas P. Kelly Chief Financial Officer, Treasurer & Executive VP
James A. Bristol Chairman
Daniel L. Flynn President, Chief Executive Officer & Director
Stephen B. Ruddy Chief Technical Officer & SVP
Sector and Competitors
1st jan.Capi. (M$)
DECIPHERA PHARMACEUTICALS, INC.93.86%1 266
REGENERON PHARMACEUTICALS, INC.18.08%79 719
VERTEX PHARMACEUTICALS37.53%77 456
BIONTECH SE-46.78%33 340
WUXI APPTEC CO., LTD.-39.54%29 208
GENMAB A/S1.14%22 982